Atea Pharmaceuticals(US:AVIR) Globenewswire·2025-11-05 12:00Core Viewpoint - Atea Pharmaceuticals, Inc. will host a live conference call on November 12, 2025, to report its third-quarter financial results and provide a business update [1]. Company Overview - Atea Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing oral antiviral therapies for serious viral infections [3]. - The company utilizes a proprietary nucleos(t)ide prodrug platform to develop novel product candidates targeting single-stranded RNA viruses, which are significant causes of serious viral diseases [3]. - Atea's lead program includes bemnifosbuvir, a nucleotide analog polymerase inhibitor, and ruzasvir, an NS5A inhibitor, aimed at treating Hepatitis C Virus (HCV) [3]. Conference Call Details - The conference call will take place at 4:30 p.m. ET on November 12, 2025, and will be accessible via registration or through the company's website [2]. - Participants can join the call by dialing specific telephone numbers and using a designated conference ID [2]. - An archive of the audio webcast will be available on the company's website approximately two hours after the call and will remain accessible for at least 90 days [2].